Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus

Dang M. Nguyen, Hashem B. El-Serag, Louise Henderson, Daniel Stein, Achyut K Bhattacharyya, Richard E. Sampliner

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Background & Aims: Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE. Methods: A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005). Results: We examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer. Conclusions: PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.

Original languageEnglish (US)
Pages (from-to)1299-1304
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume7
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Barrett Esophagus
Proton Pump Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anti-Inflammatory Agents
Neoplasms
Aspirin
Pharmaceutical Preparations
Prescriptions
Adenocarcinoma
Chemoprevention
Esophageal Neoplasms
Observational Studies
Therapeutics
Retrospective Studies
Regression Analysis
Incidence

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus. / Nguyen, Dang M.; El-Serag, Hashem B.; Henderson, Louise; Stein, Daniel; Bhattacharyya, Achyut K; Sampliner, Richard E.

In: Clinical Gastroenterology and Hepatology, Vol. 7, No. 12, 12.2009, p. 1299-1304.

Research output: Contribution to journalArticle

Nguyen, Dang M. ; El-Serag, Hashem B. ; Henderson, Louise ; Stein, Daniel ; Bhattacharyya, Achyut K ; Sampliner, Richard E. / Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus. In: Clinical Gastroenterology and Hepatology. 2009 ; Vol. 7, No. 12. pp. 1299-1304.
@article{89b966c7a5f54c17828d1e22a63c6966,
title = "Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus",
abstract = "Background & Aims: Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE. Methods: A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005). Results: We examined 344 patients diagnosed with BE (mean age 61 years, 90.4{\%} Caucasian, 94.2{\%} male). After BE diagnosis, 67.2{\%} of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1{\%} were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3{\%} were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer. Conclusions: PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.",
author = "Nguyen, {Dang M.} and El-Serag, {Hashem B.} and Louise Henderson and Daniel Stein and Bhattacharyya, {Achyut K} and Sampliner, {Richard E.}",
year = "2009",
month = "12",
doi = "10.1016/j.cgh.2009.06.001",
language = "English (US)",
volume = "7",
pages = "1299--1304",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus

AU - Nguyen, Dang M.

AU - El-Serag, Hashem B.

AU - Henderson, Louise

AU - Stein, Daniel

AU - Bhattacharyya, Achyut K

AU - Sampliner, Richard E.

PY - 2009/12

Y1 - 2009/12

N2 - Background & Aims: Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE. Methods: A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005). Results: We examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer. Conclusions: PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.

AB - Background & Aims: Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE. Methods: A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005). Results: We examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer. Conclusions: PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.

UR - http://www.scopus.com/inward/record.url?scp=70849132813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849132813&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2009.06.001

DO - 10.1016/j.cgh.2009.06.001

M3 - Article

VL - 7

SP - 1299

EP - 1304

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 12

ER -